Neoadjuvant therapy of renal cell carcinoma: A novel treatment option in the era of targeted therapy?

International Journal of Urology

Volumn 19, Issue 10, 2012, Pages 903-907

  Schrader, Andres J ^a   Steffens, Sandra ^b   Schnoeller, Thomas J ^a   Schrader, Mark ^a   Kuczyk, Markus A ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cancer; Kidney; Neoadjuvant; Renal cell carcinoma; Targeted agents

Indexed keywords

BEVACIZUMAB; ERLOTINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CAVA VEIN DISEASE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; KIDNEY CARCINOMA; KIDNEY FIBROSIS; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; MORBIDITY; MULTIPLE CYCLE TREATMENT; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUMOR GROWTH; TUMOR THROMBUS; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; SIROLIMUS; VENA CAVA, INFERIOR;

EID: 84866744450     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03065.x     Document Type: Review

References (27)

1. National-Cancer-Institute. Dictionary of Cancer Terms at the National Institutes of Health (NIH). 2012.
2. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 2004; 171: 1071-6.
3. Mizutani Y. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. Int. J. Urol. 2009; 16: 444-8.
4. Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int. 2010; 106: 6-22.
5. Shuch B, Riggs SB, LaRochelle JC etal. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008; 102: 692-6.
6. Gorin MA, Ekwenna O, Soloway MS, Ciancio G. Dramatic Reduction in Tumor Burden with Neoadjuvant Sunitinib Prior to Bilateral Nephron-sparing Surgery. Urology 2012; 79: e11.
7. Silberstein JL, Millard F, Mehrazin R etal. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010; 106: 1270-6.
8. Hellenthal NJ, Underwood W, Penetrante R etal. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol. 2010; 184: 859-64.
9. Bex A, van der Veldt AA, Blank C etal. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J. Urol. 2009; 27: 533-9.
10. Powles T, Kayani I, Blank C etal. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann. Oncol. 2011; 22: 1041-7.
11. Cowey CL, Amin C, Pruthi RS etal. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 2010; 28: 1502-7.
12. Abel EJ, Culp SH, Tannir NM etal. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol. 2011; 59: 10-15.
13. Jonasch E, Wood CG, Matin SF etal. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 4076-81.
14. Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol. Oncol. 2011; doi:10.1016/j.urolonc.2011.01.005.
15. Ansari J, Doherty A, McCafferty I, Wallace M, Deshmukh N, Porfiri E. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin. Genitourin. Cancer 2009; 7: E39-41.
16. Thomas AA, Rini BI, Stephenson AJ etal. Surgical resection of renal cell carcinoma after targeted therapy. J. Urol. 2009; 182: 881-6.
17. Margulis V, Matin SF, Tannir N etal. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 2008; 180: 94-8.
18. Chapin BF, Delacroix SE Jr, Culp SH etal. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur. Urol. 2011; 60: 964-71.
19. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009; 115: 2355-60.
20. Karakiewicz PI, Suardi N, Jeldres C etal. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol. 2008; 53: 845-8.
21. Di Silverio F, Sciarra A, Parente U etal. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol. Int. 2008; 80: 451-3.
22. Kondo T, Hashimoto Y, Kobayashi H etal. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Jpn. J. Clin. Oncol. 2010; 40: 1173-9.
23. Harshman LC, Srinivas S, Kamaya A, Chung BI. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat. Rev. Urol. 2009; 6: 338-43.
24. Robert G, Gabbay G, Bram R etal. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur. Urol. 2009; 55: 1477-80.
25. Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 2010; 49: 520-3.
26. Cost NG, Delacroix SE Jr, Sleeper JP etal. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur. Urol. 2011; 59: 912-18.
27. Belgrano E, Trombetta C, Siracusano S, Carmignani G, Martorana G, Liguori G. Surgical Management of Renal Cell Carcinoma (RCC) with Vena Cava Tumour Thrombus. Eur. Urol. Suppl. 2006; 5: 610-18.